Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002) [Phase 1]
A Phase 1 study evaluating single doses of Frespaciguat (MK-5475) on pulmonary vascular resistance in patients with pulmonary arterial hyper…
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension [Phase 3]
This clinical trial update reports the completion of a Phase 3 study evaluating the long-term safety and tolerability of ACT 064992 in patie…
-
CLINICAL_TRIALS trial_result · 2022-01-12Clinical Trial Update: Oral CXA-10 in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 trial update for oral CXA-10 in pulmonary arterial hypertension; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-12-22Clinical Trial Update: Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 clinical trial update reporting long-term safety and efficacy of ralinepag in pulmonary arterial hypertension.
-
FDA approval · 2021-11-04FDA Approved: TADALAFIL — Original Application (Burel Pharmaceuticals, LLC)
The FDA approved a generic tadalafil product under an original ANDA for Burel Pharmaceuticals, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-10-25FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for OPSUMIT (macitentan) by Actelion Pharmaceuticals US, Inc. The approval indicates changes request…
-
FDA approval · 2021-10-25FDA Approved: UPTRAVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for UPTRAVI (selexipag) from Actelion Pharmaceuticals US, Inc., indicating an updated label or e…
-
FDA approval · 2021-08-19FDA Approved: UPTRAVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for UPTRAVI (selexipag) from Actelion Pharmaceuticals US, Inc.
-
FDA approval · 2021-07-30FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)
The FDA has approved a supplemental application for Remodulin (treprostinil) filed by United Therapeutics Corporation.
-
FDA approval · 2021-07-29FDA Approved: UPTRAVI — Original Application (Actelion Pharmaceuticals US, Inc.)
FDA approved UPTRAVI (selexipag) from Actelion Pharmaceuticals US, Inc. in an original application for the treatment of pulmonary arterial h…
-
FDA approval · 2021-07-29FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, Inc., resulting in labeling changes.
-
CLINICAL_TRIALS trial_result · 2021-07-23Clinical Trial Update: Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT [Phase 2]
A Phase 2 clinical trial (LARIAT) evaluating Bardoxolone Methyl in patients with pulmonary hypertension has completed and results have been …
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: A Mobile Health Intervention in Pulmonary Arterial Hypertension [NA]
Clinical trial update for a mobile health intervention in pulmonary arterial hypertension; study completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-21Clinical Trial Update: Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants [Phase 3]
Phase 3 study assessing pharmacokinetic effects of QTI571 on sildenafil and bosentan in pulmonary arterial hypertension; results posted.
-
FDA approval · 2021-06-08FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approves a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, Inc., resulting in changes to the product's lab…
-
FDA approval · 2021-06-08FDA Approved: AMBRISENTAN — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Ambrisentan from Actavis Pharma, Inc., related to its approved generic product.
-
FDA approval · 2021-06-08FDA Approved: AMBRISENTAN — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Ambrisentan from Mylan Pharmaceuticals Inc., indicating regulatory approval of the supplemental …
-
FDA approval · 2021-06-08FDA Approved: AMBRISENTAN — Supplemental Application (Zydus Lifesciences Limited)
The FDA approved a supplemental application for ambrisentan from Zydus Lifesciences Limited, resulting in a generic version of ambrisentan b…
-
FDA approval · 2021-06-08FDA Approved: AMBRISENTAN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for ambrisentan from Sun Pharmaceutical Industries, Inc., under an ANDA.
-
FDA approval · 2021-06-08FDA Approved: AMBRISENTAN — Supplemental Application (Sigmapharm Laboratories, LLC)
FDA approved a supplemental application for a generic version of ambrisentan (AMBRISENTAN) from Sigmapharm Laboratories, LLC.
-
FDA approval · 2021-06-08FDA Approved: AMBRISENTAN — Supplemental Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s supplemental application for ambrisentan, allowing the generic version to be marketed in the United States…
-
FDA approval · 2021-05-26FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) submitted by Actelion Pharmaceuticals US, Inc.
-
CLINICAL_TRIALS trial_result · 2021-05-17Clinical Trial Update: Riociguat in Children With Pulmonary Arterial Hypertension (PAH) [Phase 3]
Phase 3 trial update for riociguat in children with pulmonary arterial hypertension, with results posted in May 2021 and the study currently…
-
FDA approval · 2021-05-11FDA Approved: SILDENAFIL — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' original ANDA for a sildenafil powder product, a generic version of sildenafil.
-
CLINICAL_TRIALS trial_result · 2021-05-10Clinical Trial Update: An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension [Phase 3]
Open-label extension trial of UT-15C sustained-release in pulmonary arterial hypertension completed; results posted.